Embecta Corp. (NASDAQ:EMBC) Receives $11.00 Consensus Target Price from Analysts

Embecta Corp. (NASDAQ:EMBC) has been given an average recommendation of “Strong Sell” by the five research firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation and two have assigned a hold recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $11.00.

EMBC has been the topic of a number of recent research reports. Mizuho lowered their price objective on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Wall Street Zen cut shares of Embecta from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Zacks Research downgraded shares of Embecta from a “hold” rating to a “strong sell” rating in a research report on Friday, May 8th. Weiss Ratings cut shares of Embecta from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, May 6th. Finally, Bank of America cut their price target on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a research report on Monday, May 18th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of EMBC. Bank of America Corp DE grew its stake in Embecta by 45.7% in the first quarter. Bank of America Corp DE now owns 374,416 shares of the company’s stock valued at $3,310,000 after purchasing an additional 117,448 shares in the last quarter. Amundi raised its stake in shares of Embecta by 123.3% during the 1st quarter. Amundi now owns 23,798 shares of the company’s stock worth $210,000 after purchasing an additional 13,139 shares in the last quarter. Parvin Asset Management LLC raised its stake in shares of Embecta by 11,010.9% during the 1st quarter. Parvin Asset Management LLC now owns 20,333 shares of the company’s stock worth $180,000 after purchasing an additional 20,150 shares in the last quarter. Saba Capital Management L.P. boosted its holdings in shares of Embecta by 10.3% in the 1st quarter. Saba Capital Management L.P. now owns 384,609 shares of the company’s stock valued at $3,400,000 after buying an additional 36,000 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp boosted its holdings in shares of Embecta by 111.8% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 56,645 shares of the company’s stock valued at $501,000 after buying an additional 29,900 shares during the last quarter. 93.83% of the stock is owned by institutional investors and hedge funds.

Embecta Price Performance

EMBC stock opened at $3.22 on Tuesday. The stock has a market capitalization of $191.04 million, a P/E ratio of 1.69 and a beta of 0.83. The business has a 50-day moving average of $3.27 and a 200-day moving average of $7.79. Embecta has a fifty-two week low of $2.77 and a fifty-two week high of $15.55.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.15). Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The firm had revenue of $221.80 million for the quarter, compared to the consensus estimate of $235.67 million. During the same quarter in the previous year, the business posted $0.70 earnings per share. The firm’s quarterly revenue was down 14.4% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. Equities analysts expect that Embecta will post 1.62 EPS for the current year.

Embecta Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 15th. Investors of record on Thursday, May 28th were given a $0.01 dividend. The ex-dividend date of this dividend was Thursday, May 28th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 1.2%. Embecta’s payout ratio is currently 2.11%.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.